Influence of the 5-HT2C receptor antagonist, S13-242084, in tests of anxiety

被引:113
作者
Martin, JR
Ballard, TM
Higgins, GA
机构
[1] F Hoffmann La Roche Ltd, Pharma Div, Preclin CNS Dept, PRBN S, CH-4070 Basel, Switzerland
[2] F Hoffmann La Roche Ltd, Pharma Div, Neurosci Dept, CH-4070 Basel, Switzerland
关键词
5-HT2C receptor antagonist; SB-242084; fluoxetine; Ro60-0175; anxiety models; CER;
D O I
10.1016/S0091-3057(01)00713-4
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The 5-HT2C antagonist SB-242084 was examined in various anxiety tests at doses based on reversal of mCPP-induced hypoactivity (0.1-3 mg/kg ip). In the elevated plus-maze task, SB-242084 exhibited signs of anxiolysis (time spent, distance travelled. and entries into open arms), but this was potentially confounded by its general increase of locomotion; alprazolam selectively affected open-arm parameters. In a Geller-Seifter conflict test, SB-242084 produced a modest, nonsignificant increase in punished responding compared to the significant effect produced by diazepam. None of the treatments significantly affected unpunished responding. In the conditioned emotional response (CER) test, SB-242084 produced an increase in the suppression ratio (SR, smaller than diazepam). Since this 5-HT2C antagonist also increased lever pressing, an additional test was conducted with amphetamine that stimulated lever pressing but, nonetheless, failed to produce any change in SR. In the fear-potentiated startle task, SB-242084 was inactive in comparison to a significant effect of diazepam. The previously described reduction of schedule-induced polydipsia by fluoxetine and 5-HT2C receptor agonist Ro60-0175 was attenuated by SB-242084 pretreatment, however, the latter compound exhibited a potent increase in polydipsia when given alone. The present results demonstrate an anxiolytic potential of SB-242084, as well as an intrinsic response-enhancing property, however, both of these effects are task dependent. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:615 / 625
页数:11
相关论文
共 41 条
[1]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[2]   MOLECULAR-BIOLOGY OF 5-HT RECEPTORS [J].
BOESS, FG ;
MARTIN, IL .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :275-317
[3]   6-chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): The first selective and brain penetrant 5-HT2C receptor antagonist [J].
Bromidge, SM ;
Duckworth, M ;
Forbes, IT ;
Ham, P ;
King, FD ;
Thewlis, KM ;
Blaney, FE ;
Naylor, CB ;
Blackburn, TP ;
Kennett, GA ;
Wood, MD ;
Clarke, SE .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (22) :3494-3496
[5]   ACUTE ADMINISTRATION OF DIAZEPAM AND BUSPIRONE IN RATS TRAINED ON CONFLICT SCHEDULES HAVING DIFFERENT DEGREES OF PREDICTABILITY [J].
COSTELLO, NL ;
CARLSON, JN ;
GLICK, SD .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (04) :787-794
[6]   ANIMAL-MODELS OF ANXIETY BASED ON CLASSICAL-CONDITIONING - THE CONDITIONED EMOTIONAL RESPONSE (CER) AND THE FEAR-POTENTIATED STARTLE EFFECT [J].
DAVIS, M .
PHARMACOLOGY & THERAPEUTICS, 1990, 47 (02) :147-165
[7]   THE ROLE OF THE AMYGDALA IN FEAR-POTENTIATED STARTLE - IMPLICATIONS FOR ANIMAL-MODELS OF ANXIETY [J].
DAVIS, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (01) :35-41
[8]   EVIDENCE THAT THE ANXIOLYTIC-LIKE EFFECTS OF CHLORDIAZEPOXIDE ON THE ELEVATED PLUS-MAZE ARE CONFOUNDED BY INCREASES IN LOCOMOTOR-ACTIVITY [J].
DAWSON, GR ;
CRAWFORD, SP ;
COLLINSON, N ;
IVERSEN, SD ;
TRICKLEBANK, MD .
PSYCHOPHARMACOLOGY, 1995, 118 (03) :316-323
[9]   The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats -: A comparison with other anxiolytic agents [J].
Dekeyne, A ;
Brocco, M ;
Adhumeau, A ;
Gobert, A ;
Millan, MJ .
PSYCHOPHARMACOLOGY, 2000, 152 (01) :55-66
[10]   Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175:: a pharmacological analysis [J].
Dekeyne, A ;
Girardon, S ;
Millan, MJ .
NEUROPHARMACOLOGY, 1999, 38 (03) :415-423